NEWSROOM

Healthcare

SS Innovations Announces Completion of BDO Audit Process and Issues Update on Plans for NASDAQ Uplisting

SS Innovations Announces Completion of BDO Audit Process and Issues Update on Plans for NASDAQ Uplisting

Dec 11, 2024

FORT LAUDERDALE, Fla., Dec. 11, 2024 - PRISM MediaWire - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, today announced that its new independent registered public accounting firm, BDO India LLP (“BDO”), has completed the re-audit of the Company’s consolidated financial statements for the years ended December...

India’s First CDSCO Certified Robotic System for Telesurgery: SSi Mantra Leads the Way

India’s First CDSCO Certified Robotic System for Telesurgery: SSi Mantra Leads the Way

Dec 10, 2024

SS Innovations becomes the first and only company in India to receive regulatory approval for Telesurgery and Teleproctoring capabilities of a surgical robotic system, its SSi Mantra, marking a significant achievement in surgical robotics SS Innovations reinforces India's position as a hub for technological innovation in healthcare using the SSi Mantra - Made in India, for the World The SSi Mantra integrates innovative advancements in robotic surgery, offering surgeons enhanced precision and...

Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

Dec 9, 2024

January 13-16, 2025, San Francisco, CA IRVINE, Calif., December 9, 2024 - PRISM MediaWire - Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P. Morgan Week,” coinciding with the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, from January 13 - 16, 2025. During this period, Oncocyte will host one-on-one meetings with interested investors....

Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study

Dec 6, 2024

IRVINE, Calif., Dec. 04, 2024 - PRISM MediaWire - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay. In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number aberrations (SCNAs) in cerebrospinal fluid. For context, copy number...

Former Merck USA President Joins Klotho Neurosciences’ Board of Directors

Former Merck USA President Joins Klotho Neurosciences’ Board of Directors

Dec 3, 2024

Highly Accomplished Pharmaceutical Leader, Riad El-Dada, Further Enhances Board Expertise NEW YORK, Dec. 03, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer’s, and Parkinson’s, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors. With decades of leadership in the pharmaceutical...

Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus

Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus

Dec 3, 2024

Peer-reviewed article highlights potential treatment for OLP with focus on localized drug delivery PITTSBURGH, Dec. 03, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company dedicated to addressing serious diseases with significant unmet needs, today announced the publication of a peer-reviewed paper in CUREUS. Titled “Rationale for the Use of Topical Calcineurin Inhibitors in the Management of Oral Lichen Planus and Mucosal...

Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms

Dec 2, 2024

Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population Study shows that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies Early detection of transplant rejection is growing in significance as novel therapeutic treatments show promising early results in antibody mediated rejection. Study published in Nephrology Dialysis...

Halberd Update on WatchDawg® PTSD Treatment

Halberd Update on WatchDawg® PTSD Treatment

Dec 2, 2024

Next Phase Pilot Study Jackson Center, PA, December 2, 2024 - PRISM MediaWire - Halberd Corporation (OTC PINK: HALB) previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. The results of that study can be found here. Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software...

SS Innovations Marks a Milestone with First Robotic Cardiac Surgery in Indonesia

SS Innovations Marks a Milestone with First Robotic Cardiac Surgery in Indonesia

Nov 26, 2024

SS Innovations marks a milestone with the successful completion of Indonesia’s first robotic cardiac surgery using its SSi Mantra Surgical Robotic System. Dr. Sudhir Srivastava, Founder, Chairman, and CEO of SS Innovations successfully performed the first Beating Heart Totally Endoscopic Coronary Artery Bypass (TECAB) in Indonesia, a significant achievement in the field of robotic cardiac surgery. The developed and made-in-India SSi Mantra Surgical Robotic System highlights India’s position as...

BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts

BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts

Nov 25, 2024

Company continues to advance its placental-derived product portfolio with the first patent granted in the fenestrated wound care market POMPANO BEACH, Fla., Nov. 25, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for...

BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

Nov 20, 2024

Additions of ProgenaMatrix®and revyve™ Antimicrobial Wound Gel part of planned expansion of BioStem’s commercial product portfolio POMPANO BEACH, Fla., November 20, 2024 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, today announced the signing of a Letter of Intent (LOI) to acquire commercial-stage products and development technologies from ProgenaCare Global...

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Nov 13, 2024

Company advancing late-stage clinical programs with novel therapies that target underserved heart diseases NEW YORK, November 13, 2024 - PRISM MediaWire - PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL) has been added to the PRISM Emerging Biotech Index, which spotlights companies leading innovation and creating market impact within the biotech sector. Cardiol’s focus on anti-inflammatory and...

American Shared Hospital Services Reports Third Quarter 2024 Financial Results

American Shared Hospital Services Reports Third Quarter 2024 Financial Results

Nov 13, 2024

- Revenue increases 36.3% period over period - Conference Call on November 13th at 1:00 pm ET SAN FRANCISCO, CA, November 13, 2024 ‒ American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent Highlights Total revenue in...

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

Nov 12, 2024

Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phase FDA pre-submission process for approval of kitted clinical test is underway IRVINE, Calif., Nov. 12, 2024 - PRISM MediaWire - Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today published the following letter to shareholders in conjunction with its third...

PPJ Healthcare Enterprises Expands Business with New Health & Wellness Franchises

PPJ Healthcare Enterprises Expands Business with New Health & Wellness Franchises

Nov 12, 2024

TAMPA, Florida, November 12, 2024 - PRISM MediaWire - PPJ Healthcare Enterprises Inc. (OTC Pink: PPJE) announces today that the company is adding Health and Wellness Franchises to its business plans. Ms. Basu noted: "Our company has invested several years in research and development of innovative health and wellness services to provide effective relief for Americans facing undiagnosed conditions. We are excited to introduce various franchise options and are on track to launch our first center...

BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts

BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million

Nov 12, 2024

Company reports third sequential quarter of record growth, contributing to a record total of $199.0 million in revenue for the first nine-months of 2024 Achieves third consecutive quarter of positive GAAP net income of $6.8 million or $0.42 per share. Generated Q3 2024 Adjusted EBITDA of $9.9 million Financial Results Conference Call and Webcast on Tuesday, November 12, 2024, at 4:30 pm ET POMPANO BEACH, FL, November 12, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (the...

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

Nov 12, 2024

PITTSBURGH, November 12, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform will be officially issued by the U.S. Patent and Trademark Office (USPTO) on November 12, 2024. This patent, titled "Delivery of Agents Using Metastable Liposomes," covers...

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Nov 6, 2024

Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Nov. 6, 2024 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will also host a conference call and webcast on Tuesday, November 12, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss...

American Shared Hospital Services Reports Third Quarter 2024 Financial Results

American Shared Hospital Services Announces Third Quarter 2024 Earnings Conference Call

Nov 6, 2024

Call Scheduled November 13th at 1:00 PM ET SAN FRANCISCO, November 6, 2024 - PRISM MediaWire - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a conference call to discuss its third quarter 2024 financial results on November 13th at 1:00 pm ET / 10:00 am PT. The third quarter 2024 financial...

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Nov 1, 2024

PITTSBURGH, PA, November 1, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company’s certificate of...

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

Oct 29, 2024

The pricing announcement from the Center for Medicare Services became effective on October 1, 2024, and allows BioStem to begin marketing initiatives with Venture Medical POMPANO BEACH, Fla., October 29, 2024 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces it will initiate a nationwide launch of Vendaje AC® with Venture Medical,...

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 28, 2024

Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., October 28, 2024 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that it will release its Third quarter 2024 financial results on Tuesday, November 12, 2024, and host a conference call and webcast at 4:30 PM ET to discuss the results. The webcast will...

NeuroOne® Medical Technologies to Present at the 2024 ThinkEquity Conference

NeuroOne® Medical Technologies to Present at the 2024 ThinkEquity Conference

Oct 24, 2024

EDEN PRAIRIE, Minn., October 24, 2024 - PRISM MediaWire - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate...

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference

Oct 24, 2024

Princeton, NJ, October 24, 2024 - PRISM MediaWire - Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other...

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Oct 23, 2024

Glen Allen, VA, October 23, 2024 - PRISM MediaWire - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024

Oct 23, 2024

MIAMI, FL., October 23, 2024 – PRISM MediaWire - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc., a medical and technology driven company and wholly-owned subsidiary of NRx, today announced they will be featured as a participating in the ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate...

Former Merck USA President Joins Klotho Neurosciences’ Board of Directors

Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor

Oct 23, 2024

Discoverer of Klotho gene further strengths KLTO Scientific Advisory Board New York, NY, October 23, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a leading biotechnology company focused on developing cell and gene therapies for aging and age-related diseases, is proud to announce the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o, a distinguished Japanese physician-scientist, is widely recognized as the pioneer behind the discovery of the...

Innocan Pharma to Present at the 2024 ThinkEquity Conference

Innocan Pharma to Present at the 2024 ThinkEquity Conference

Oct 21, 2024

Herzliya, Israel and Calgary, Alberta, October 21, 2024 - PRISM MediaWire - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in chronic pain management via Liposomal CBD drug products, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry...

Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference

Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference

Oct 18, 2024

NEWTOWN, Pa., Oct. 18, 2024 - PRISM MediaWire - Helius Medical Technologies, Inc. (“Helius” or the “Company”) [Nasdaq: HSDT], a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it plans to participate in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals...

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment

Oct 17, 2024

Retrospective Study demonstrates clinical efficacy and statistical support for tissue processed via BioREtain to care for treatment-resistant chronic wounds Study published in the peer-reviewed journal, ‘International Wound Journal’ POMPANO BEACH, Fla., Oct. 17, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived biologics for advanced wound care, announces breakthrough...